1
|
Broutin M, Costa F, Peltier S, Maye J, Versillé N, Klonjkowski B. An Oil-Based Adjuvant Improves Immune Responses Induced by Canine Adenovirus-Vectored Vaccine in Mice. Viruses 2023; 15:1664. [PMID: 37632007 PMCID: PMC10458467 DOI: 10.3390/v15081664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Revised: 07/18/2023] [Accepted: 07/26/2023] [Indexed: 08/27/2023] Open
Abstract
There is a significant need for highly effective vaccines against emerging and common veterinary infectious diseases. Canine adenovirus type 2 (CAV2) vectors allow rapid development of multiple vaccines and have demonstrated their potential in animal models. In this study, we compared the immunogenicity of a non-replicating CAV2 vector encoding the rabies virus glycoprotein with and without MontanideTM ISA 201 VG, an oil-based adjuvant. All vaccinated mice rapidly achieved rabies seroconversion, which was associated with complete vaccine protection. The adjuvant increased rabies antibody titers without any significant effect on the anti-CAV2 serological responses. An RT2 Profiler™ PCR array was conducted to identify host antiviral genes modulated in the blood samples 24 h after vaccination. Functional analysis of differentially expressed genes revealed the up-regulation of the RIG-I, TLRs, NLRs, and IFNs signaling pathways. These results demonstrate that a water-in-oil-in-water adjuvant can shape the immune responses to an antigen encoded by an adenovirus, thereby enhancing the protection conferred by live recombinant vaccines. The characterization of early vaccine responses provides a better understanding of the mechanisms underlying the efficacy of CAV2-vectored vaccines.
Collapse
Affiliation(s)
- Manon Broutin
- UMR Virologie, INRAE, ANSES, EnvA, 94700 Maisons-Alfort, France; (M.B.); (F.C.)
- SEPPIC Paris La Défense, 92250 La Garenne Colombes, France; (S.P.); (J.M.); (N.V.)
| | - Fleur Costa
- UMR Virologie, INRAE, ANSES, EnvA, 94700 Maisons-Alfort, France; (M.B.); (F.C.)
| | - Sandy Peltier
- SEPPIC Paris La Défense, 92250 La Garenne Colombes, France; (S.P.); (J.M.); (N.V.)
| | - Jennifer Maye
- SEPPIC Paris La Défense, 92250 La Garenne Colombes, France; (S.P.); (J.M.); (N.V.)
| | - Nicolas Versillé
- SEPPIC Paris La Défense, 92250 La Garenne Colombes, France; (S.P.); (J.M.); (N.V.)
| | - Bernard Klonjkowski
- UMR Virologie, INRAE, ANSES, EnvA, 94700 Maisons-Alfort, France; (M.B.); (F.C.)
| |
Collapse
|
2
|
De Vleeschauwer AR, Zhou X, Lefebvre DJ, Garnier A, Watier F, Pignon C, Lacour SA, Zientara S, Bakkali-Kassimi L, De Clercq K, Klonjkowski B. A canine adenovirus type 2 vaccine vector confers protection against foot-and-mouth disease in guinea pigs. Vaccine 2018; 36:2193-2198. [PMID: 29544690 DOI: 10.1016/j.vaccine.2018.02.074] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2017] [Revised: 02/07/2018] [Accepted: 02/16/2018] [Indexed: 11/30/2022]
Abstract
Vaccination is a key element in the control of foot-and-mouth disease (FMD). The majority of the antigenic sites that induce protective immune responses are localized on the FMD virus (FMDV) capsid that is formed by four virus-encoded structural proteins, VP1 to VP4. In the present study, recombinant canine adenovirus type 2 (CAV2)-based FMD vaccines, Cav-P1/3C R° and Cav-VP1 R°, respectively expressing the structural P1 precursor protein along with the non-structural 3C protein or expressing the structural VP1 protein of the FMDV strain O/FRA/1/2001, were evaluated as novel vaccines against FMD. A strong humoral immune response was elicited in guinea pigs (GP) following immunization with Cav-P1/3C R°, while administration of Cav-VP1 R° did not induce a satisfying antibody response in GP or mice. GP were then used as an experimental model for the determination of the protection afforded by the Cav-P1/3C R° vaccine against challenge with the FMDV strain O1 Manisa/Turkey/1969. The Cav-P1/3C R° vaccine protected GP from generalized FMD to a similar extent as a high potency double-oil emulsion O1 Manisa vaccine. The results of the present study show that CAV2-based vector vaccines can express immunogenic FMDV antigens and offer protection against generalized FMD in GP. This suggest that Cav-P1/3C R° FMDV vaccine may protect natural host species from FMD. In combination with an appropriate diagnostic test, the Cav-P1/3C R° FMDV vaccine may also serve as a marker vaccine to differentiate vaccinated from infected animals.
Collapse
Affiliation(s)
- Annebel R De Vleeschauwer
- Vesicular and Exotic Diseases Unit, Veterinary and Agrochemical Research Centre (CODA-CERVA), Groeselenberg 99, 1180 Brussels, Belgium
| | - Xiaocui Zhou
- UMR Virologie, INRA, ANSES, École Nationale Vétérinaire d'Alfort, Maisons-Alfort, F-94700, France; Laboratory of Zoonoses, China Animal Health and Epidemiology Centre, 369 Nanjing Road, Qingdao, China
| | - David J Lefebvre
- Vesicular and Exotic Diseases Unit, Veterinary and Agrochemical Research Centre (CODA-CERVA), Groeselenberg 99, 1180 Brussels, Belgium
| | - Annabelle Garnier
- UMR Virologie, INRA, ANSES, École Nationale Vétérinaire d'Alfort, Maisons-Alfort, F-94700, France
| | - Fleur Watier
- UMR Virologie, INRA, ANSES, École Nationale Vétérinaire d'Alfort, Maisons-Alfort, F-94700, France
| | - Charly Pignon
- Exotics Medicine Service, École Nationale Vétérinaire d'Alfort, Maisons-Alfort, F-94700, France
| | - Sandrine A Lacour
- UMR Virologie, INRA, ANSES, École Nationale Vétérinaire d'Alfort, Maisons-Alfort, F-94700, France
| | - Stephan Zientara
- UMR Virologie, INRA, ANSES, École Nationale Vétérinaire d'Alfort, Maisons-Alfort, F-94700, France
| | - Labib Bakkali-Kassimi
- UMR Virologie, INRA, ANSES, École Nationale Vétérinaire d'Alfort, Maisons-Alfort, F-94700, France
| | - Kris De Clercq
- Vesicular and Exotic Diseases Unit, Veterinary and Agrochemical Research Centre (CODA-CERVA), Groeselenberg 99, 1180 Brussels, Belgium
| | - Bernard Klonjkowski
- UMR Virologie, INRA, ANSES, École Nationale Vétérinaire d'Alfort, Maisons-Alfort, F-94700, France.
| |
Collapse
|
3
|
Warimwe GM, Lorenzo G, Lopez-Gil E, Reyes-Sandoval A, Cottingham MG, Spencer AJ, Collins KA, Dicks MDJ, Milicic A, Lall A, Furze J, Turner AV, Hill AVS, Brun A, Gilbert SC. Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice. Virol J 2013; 10:349. [PMID: 24304565 PMCID: PMC4235025 DOI: 10.1186/1743-422x-10-349] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2013] [Accepted: 11/29/2013] [Indexed: 02/07/2023] Open
Abstract
Background Rift Valley Fever (RVF) is a viral zoonosis that historically affects livestock production and human health in sub-Saharan Africa, though epizootics have also occurred in the Arabian Peninsula. Whilst an effective live-attenuated vaccine is available for livestock, there is currently no licensed human RVF vaccine. Replication-deficient chimpanzee adenovirus (ChAd) vectors are an ideal platform for development of a human RVF vaccine, given the low prevalence of neutralizing antibodies against them in the human population, and their excellent safety and immunogenicity profile in human clinical trials of vaccines against a wide range of pathogens. Methods Here, in BALB/c mice, we evaluated the immunogenicity and efficacy of a replication-deficient chimpanzee adenovirus vector, ChAdOx1, encoding the RVF virus envelope glycoproteins, Gn and Gc, which are targets of virus neutralizing antibodies. The ChAdOx1-GnGc vaccine was assessed in comparison to a replication-deficient human adenovirus type 5 vector encoding Gn and Gc (HAdV5-GnGc), a strategy previously shown to confer protective immunity against RVF in mice. Results A single immunization with either of the vaccines conferred protection against RVF virus challenge eight weeks post-immunization. Both vaccines elicited RVF virus neutralizing antibody and a robust CD8+ T cell response. Conclusions Together the results support further development of RVF vaccines based on replication-deficient adenovirus vectors, with ChAdOx1-GnGc being a potential candidate for use in future human clinical trials.
Collapse
|